Key Takeaways
Medpace Holdings Inc. (NASDAQ: MEDP) faces a securities fraud class action lawsuit after its stock price fell as much as 23 percent following revised business outlooks.
"As alleged, in truth, Medpace’s cancellations had increased causing its book-to-bill ratio to decline," Bleichmar Fonti & Auld LLP, one of the law firms that filed a suit, said in a statement.
The lawsuit, filed in the U.S. District Court for the Southern District of Ohio, covers investors who purchased Medpace stock between April 22, 2025, and February 9, 2026. The company's stock dropped nearly 16 percent on February 10 after it revealed a lower book-to-bill ratio of 1.04 for the fourth quarter of 2025 due to elevated cancellations.
Shares tumbled another 23 percent during afternoon trading on April 23 after reports of continued high cancellations, a book-to-bill ratio as low as 0.88 for the first quarter of 2026, and the announced resignation of President Jesse Geiger.
The core of the allegations, brought forth by law firms including Bleichmar Fonti & Auld LLP and Bronstein, Gewirtz & Grossman, LLC, is that Medpace made materially false and misleading statements about its business prospects. The complaints focus on the company allegedly understating its service cancellation rates while portraying an overly optimistic book-to-bill ratio of approximately 1.15 in public communications.
The negative disclosures led to sharp declines in investor confidence and a series of analyst downgrades. According to MarketBeat data, the consensus rating for Medpace has shifted to "Hold," with firms like Leerink Partners and TD Cowen recently cutting their price targets.
Adding to investor concerns, company President Jesse J. Geiger sold 31,707 shares of stock on March 17 for a total of $14.4 million, reducing his holdings by nearly 68 percent. Geiger later announced his intention to resign after 18 years with the company.
The lawsuits seek to recover damages for investors who suffered losses. The deadline for investors to petition the court to be appointed as a lead plaintiff is June 8, 2026.
The lawsuits compound a period of intense pressure on the company, which has seen its market capitalization fall to $11.72 billion. Investors will watch for the court's decision on the lead plaintiff appointment after the June 8 deadline.
This article is for informational purposes only and does not constitute investment advice.
